Changes are needed in the way drugs are evaluated according to experts who say patients and health services are getting a poor return on their investment into new drugs. In an article published on bmj.com today they say the industry talks about the expense of bringing a new product to the market but it is the public who provide most of the support for developing and evaluating new drugs.
Read more on CALL FOR BETTER RETURN FOR HEALTH SERVICES FROM INVESTMENT IN DRUGS…